Bunnage Mark E. 4

What Happened

• Mark E. Bunnage, EVP and Chief Scientific Officer of Vertex Pharmaceuticals (VRTX), reported a disposition on Feb 13, 2026 in which 2,283 shares were withheld to satisfy tax liability associated with an option exercise/award. The shares were valued at $487.76 each, totaling $1,113,556. The filing reports this as a tax-withholding disposition (transaction code F), not an open-market sale.

Key Details

• Transaction date and price: 2026-02-13; 2,283 shares at $487.76 per share.
• Total value withheld: $1,113,556.
• Transaction code: F (payment of exercise price or tax liability — shares withheld to cover taxes).
• Shares owned after transaction: not specified in the supplied filing details.
• Filing timeliness: Report filed 2026-02-18 for a 2026-02-13 transaction — this appears to be filed after the standard two-business-day window (late filing).

Context

• This was a tax-withholding disposition (common when executives exercise options or vest restricted stock) rather than a targeted sale into the open market; it usually reflects payroll tax obligations rather than a directional bet on the stock. Retail investors should note the routine administrative nature of such transactions, and that the late filing may be a reporting compliance issue but does not by itself indicate trading intent.